Perioperative management of patient with intracoronary stent presenting for noncardiac surgery

• Published in: Annals of cardiac anaesthesia Vol. 19; no. 1; pp. 122 - 131
• Main Authors: Gurajala, Indira, Gopinath, Ramachandran
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.01.2016; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Antiplatelet therapy; Coronary stent; Noncardiac surgery; Balloon angioplasty; Cardiologists; Coronary Vessels; Elective Surgical Procedures; Health aspects; Humans; Perioperative Care - methods; Platelet Aggregation Inhibitors - therapeutic use; Practice; Review; Risk Assessment; Stents; Surgical Procedures, Operative - methods
• ISSN: 0971-9784; 0974-5181
• DOI: 10.4103/0971-9784.173028

As the number of percutaneous coronary interventions increase annually, patients with intracoronary stents (ICS) who present for noncardiac surgery (NCS) are also on the rise. ICS is associated with stent thrombosis (STH) and requires mandatory antiplatelet therapy to prevent major adverse cardiac events. The risks of bleeding and ischemia remain significant and the management of these patients, especially in the initial year of ICS is challenging. The American College of Cardiologists guidelines on the management of patients with ICS recommend dual antiplatelet therapy (DAT) for minimal 14 days after balloon angioplasty, 30 days for bare metal stents, and 365 days for drug-eluting stents. Postponement of elective surgery is advocated during this period, but guidelines concerning emergency NCS are ambiguous. The risk of STH and surgical bleeding needs to be assessed carefully and many factors which are implicated in STH, apart from the type of stent and the duration of DAT, need to be considered when decision to discontinue DAT is made. DAT management should be a multidisciplinary exercise and bridging therapy with shorter acting intravenous antiplatelet drugs should be contemplated whenever possible. Well conducted clinical trials are needed to establish guidelines as regards to the appropriate tests for platelet function monitoring in patients undergoing NCS while on DAT.